Novogene NovoPM 2.0 Cancer Panel

Chula Vista, California-based Novogene has launched its NovoPM 2.0 Cancer Panel, a next-generation sequencing panel that analyzes 484 solid tumor-related genes and introns in 43 genes. According to the firm, the test can detect four types of genomic abnormalities (single nucleotide variation, insertions/deletions, copy number variation, and fusions), and features bioinformatics software including three algorithms specific for guiding cancer immunotherapy decision making.